Therefore, this study adopted a strict randomized controlled trial design in constructing an NSCLC brain metastasis animal model, and simulated clinical doses to compare the efficacy of the three EGFR TKIs in treating NSCLC brain metastases. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.